Simcere Pharmaceutical Net Profit Climbs 86.2% to RMB1.344 Billion

Edgen Stock·Mar 25 2026, 20:10

Share to

Share to

Copy link

Key Takeaways

Simcere Pharmaceutical (02096.HK) reported robust financial results for the full year 2025, demonstrating significant profitability and top-line growth. The company's net profit surged 86.2% to RMB1.344 billion, while revenue climbed 16.5% to RMB7.731 billion, supported by its innovative drug portfolio and licensing income.

Net profit soared 86.2% year-over-year to reach RMB1.344 billion for the full year 2025.
Full-year revenue increased 16.5% to RMB7.731 billion, led by innovative drugs and licensing income.
The company announced a final dividend of 18 cents per share, rewarding shareholders after the strong performance.

Net Profit Climbs 86.2% on Innovative Drug Sales

Simcere Pharmaceutical (02096.HK) announced a significant increase in profitability for its full-year 2025 results, with net profit reaching RMB1.344 billion. This figure represents an 86.2% surge compared to the previous year. The company's top-line performance was also strong, as revenue grew 16.5% year-over-year to RMB7.731 billion. The growth was attributed to a combination of higher revenue from its portfolio of innovative drugs, increased licensing income, and net gains from its investments. Earnings per share for the period were reported at 54 cents.

Following the strong financial performance, Simcere's board has declared a final dividend of 18 cents per share for the 2025 fiscal year. This rewards shareholders and signals confidence in the company's continued financial health. The distribution represents an increase from the RMB 0.16 final dividend paid for the 2024 fiscal year, underscoring the substantial profit growth achieved during the period and the company's commitment to returning value to investors.

Net Profit Climbs 86.2% on Innovative Drug Sales

Board Approves Final Dividend of 18 Cents Per Share